
    
      Studies have shown that esketamine can treat clinical refractory depression, the drug takes
      effect quickly, can quickly eliminate the patient's suicide intention, low-dose maintenance
      treatment is conducive to the stability of the patient's condition, and less adverse
      reactions, is the current hot spot of antidepressant drug research. Esketamine has been
      approved by FDA for the treatment of refractory and suicidal depression, but can it
      effectively prevent and treat postpartum depression? It is not clear. Based on this, this
      study aims to explore the preventive effect of prophylactic administration of esketamine on
      postpartum depression in cesarean section, and evaluate the safety of the drug.
    
  